LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Deschisă

Sector Sănătate

0.82 -2.38

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.8

Maxim

0.89

Indicatori cheie
By Trading Economics
Vânzări	-7.4M 2M
EPS	-0.34
Angajați	405

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+223.53 upside

Dividende
By Dow Jones
Următoarele câștiguri	30 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	-2.3M 114M
Deschiderea anterioară	3.2
Închiderea anterioară	0.82

Sentimentul știrilor

By Acuity

50%

97 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

0.8101 / 0.8799 Suport & Rezistență

Sangamo Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 sept. 2024, 01:45 UTC

Câștiguri

Preview -- Barron's

13 sept. 2024, 20:03 UTC

Top știri

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept. 2024, 16:52 UTC

Top știri

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept. 2024, 09:30 UTC

Top știri

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept. 2024, 07:00 UTC

Top știri

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept. 2024, 14:09 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept. 2024, 13:25 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ -2-

14 sept. 2024, 00:01 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept. 2024, 21:14 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept. 2024, 21:06 UTC

Top știri

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13 sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept. 2024, 20:44 UTC

Achiziții, Fuziuni, Preluări

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept. 2024, 20:41 UTC

Top știri

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept. 2024, 20:31 UTC

Câștiguri

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept. 2024, 20:13 UTC

Achiziții, Fuziuni, Preluări

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept. 2024, 20:10 UTC

Achiziții, Fuziuni, Preluări

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparație

Modificare preț

Sangamo Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

223.53% sus

Prognoză pe 12 luni

Medie 2.75 USD 223.53%

Maxim 5 USD

Minim 1 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSangamo Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Sangamo Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.8101 / 0.8799Suport & Rezistență

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

97 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

EBITDA

Profit operațional

Despre Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.